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Abstract: Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment 
of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with 
epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) 
or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-
PD-1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a 
metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape 
mechanisms may play an interesting role in this regard either alone or in combination with 
current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic 
non-small-cell lung cancer as well as future perspectives within this framework.
Keywords: immunotherapy, non-small-cell lung cancer, nivolumab, pembrolizumab, 
ipilimumab, clinical trials, PD1, PDL1, CTLA4
Introduction to the development of immunotherapy  
for cancer and NSCLC
According to the World Health Organization, lung cancer is currently the leading cause 
of cancer mortality worldwide and of tobacco-related death.1–3 The 5-year overall 
survival (OS) rate is only 15% for all stages.4 These results also revealed that invasion 
and metastasis are the primary causes of recurrence and death in patients with lung 
cancer.4 Historical approaches to nonspecific cytotoxic chemotherapy are associated 
with severe adverse effects (AEs), selection of drug-resistant tumor cells (TCs), and 
failure to resolve metastatic or subclinical disease.3
Lung cancer can be generally divided into small-cell lung cancer and non-small-cell 
lung cancer (NSCLC). NSCLC accounts for .80% of all lung cancers, and patients with 
this type demonstrate a limited response to chemotherapy when they are in advanced 
stages.5 Approximately 75% of all NSCLC cases are diagnosed at an advanced stage 
of the disease,6,7 which means that these patients will have a median survival time of 
4–5 months after diagnosis, and only 10% of them will survive for 1 year.8,9
Despite this scenario, the search for safe and specific NSCLC treatments found 
an opportunity in various immunotherapeutic agents. Vaccines, cytokines, and 
monoclonal antibodies (mAbs) have become promising drugs that may either help 
to generate an active immune response against neoplastic antigens or stimulate a 
nonspecific immune attack against various tumors; in addition, external antibodies 
may be used as a mechanism for a brief targeted response.2 Increased knowledge of 
the intricacies of the immune system and how it might act in synergy with conven-
tional chemotherapy has generated new perspectives for NSCLC therapy, which may 
change its prognosis.
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In recent years, many attempts have been made to 
obtain consistent benefits from tumor vaccines and cytok-
ines: belagenpumatucel-L (an allogeneic TC vaccine) and 
tecemotide (a peptide vaccine) did not meet survival end 
points over the placebo in Phase III trials.10,11 The use of IL-2 
and interferons (cytokines) generated infrequent responses, 
and these were observed in only a few types of cancers. 
Researchers question whether this limited response is actually 
caused by a tumor mechanism of immune escape.12
The last drug class, mAbs, became applicable as part of a 
very specific strategy: not as a direct immune system activa-
tor against cancerous cells but rather as an instrument to free 
T-cells from negative regulatory breaks and to promote their 
cytotoxicity so that they may bind to distinct sites.12 Research 
has revealed that the targeted proteins that are responsible for 
such negative regulations are PD-1, PD-L1, and CTLA-4. 
Ipilimumab, pembrolizumab, tremelimumab, and nivolumab 
are all immune checkpoint inhibitors that are capable of 
binding and inactivating the effects of the above-mentioned 
proteins. These drugs have demonstrated positive results in 
the treatment of many cancers and have been studied for use 
in NSCLC. The US Food and Drug Administration (FDA) 
has recently approved nivolumab for therapeutic use.13
This review aims to discuss the role and evidence of 
immune response in cancer pathology, the mechanisms of 
immune checkpoint inhibitors, clinical trials and their results 
with respect to efficacy and safety, and future perspectives 
for patients’ quality of life (QoL).
Rationale for the development 
of immunotherapies
The immune system functions as an adaptable and specific 
system that distinguishes self from nonself and attacks foreign 
pathogens and infected self tissues. The innate immune 
system acts as a nonspecific first line of defense and includes a 
vast array of components, including antigen-presenting cells 
(APCs). In contrast, the adaptive immune response results 
in the development of cytotoxic CD8+ T-cells, helper CD4+ 
T-cells, and antibody-producing plasma cells.14,15 The pres-
ence of an adaptive immune system endows vertebrates with 
a unique ability to develop highly specific responses. The 
adaptive immune system is driven by a multitude of highly 
specific antigen receptors on T-cells (T-cell receptor) and 
B-cells (B-cell receptor). The cognate binding of an antigen 
to the B- or T-cell receptor promotes the development of a 
vigorous antigen-specific immune response and the develop-
ment of long-lived memory cells. After the eradication of 
cancer, the presence of memory cells potentially prevents 
tumor regrowth, decreases metastatic spread, and can limit 
the de novo induction of a second malignancy.8
In antitumor immune responses, CD8+ T-cells and CD4+ 
T-cells recognize tumor antigens in the context of major 
histocompatibility complex class I and class II molecules, 
respectively. Following initial APC-driven activation, CD8+ 
T-cells function in cell-mediated cytotoxicity and have the 
ability to kill cells that are recognized as nonself and cells 
with altered self-antigens. It is thought that CD8+ T-cells play 
a key role in the antitumor immune response. On the contrary, 
CD4+ T-cells differentiate into several types of helper CD4+ 
T-cells. In a noninflamed environment, CD4+ T-cells can dif-
ferentiate into regulatory T-cells (T
regs
). These cells are able 
to inhibit the host’s antitumor immune response as they are 
important negative regulators of the immune system. When 
this is taken into account, T
regs
 are considered as a good target 
for cancer immunotherapy.8
Published data on animal studies have revealed that lym-
phocytes and natural killer cells contribute to host antitumor 
defense mechanisms. These data show that deficiencies in 
key immunologic molecules, such as the perforin,7 RAG2,16 
or IFN-γ,17 lead to the development of spontaneous tumors. 
These studies clarify the cellular basis of cancer immunosur-
veillance, which is a hypothesis that was proposed decades 
ago by Burnet18 and Thomas.19
A clear difference in the interpretations of Burnet and 
Thomas in regard to this hypothesis was the nature of tumor 
recognition by immune cells (ICs). Burnet considered the 
self- versus nonself-discrimination hypothesis in which the 
development of cancers is inhibited. The hypothesis devised 
by Thomas was different in that he proposed that organisms 
must possess a primary defense, similar to homograft 
rejection, against neoplasia.4 The immune surveillance 
theory, which was validated after technological advances in 
mouse genetics and mAb production, involves a set of cells 
and immune system molecules that play a role in the active 
elimination of immunogenic TCs.
However, many have acknowledged that cancer immuno-
surveillance is just one step in a larger process termed cancer 
immunoediting9,20,21 (Figure 1). This concept recognizes that 
even after the phase of elimination when the tumor escapes 
immunosurveillance, the fate of the tumor may ultimately be 
sculpted by immunity and may experience two subsequent 
phases, as follows: the equilibrium phase, during which the 
tumor may either be dormant or be immunologically sculpted 
by immune “editors” to produce new variants that carry more 
mutations, which would increase resistance to immune attack; 
this phase would be followed by the escape phase, when the 
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
21
0.
25
3.
68
 o
n 
11
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
23
immunotherapy for patients with advanced lung cancer
tumor becomes clinically detectable. The elimination of 
the tumor or the long-term control of cancer in equilibrium 
represents a potential goal for immunotherapy.21
The immune system is suppressed by several factors. 
It would be a great challenge if the elaboration of immuno-
therapeutic strategies could determine which immunosup-
pressive factors are required for the maintenance of immune 
tolerance to various types of cancers.22 The immune responses 
can be inhibited when certain TCs overproduce and express 
several molecules with proapoptotic or immune suppres-
sive properties, such as TGF-β; this protein constitutes one 
of the most important immunosuppressive factors because 
it inhibits the activation, proliferation, and activity of lym-
phocytes. In addition, IL-10, which is an anti-inflammatory 
or immunosuppressive cytokine, is associated with tumor 
growth and with the regulation of the maturation of APCs 
as well as their capacity to produce inflammatory cytokines, 
such as IL-12.23
The number or frequency of tumor-infiltrating lympho-
cytes is usually used as a prognostic factor, where an increase 
in tumor-infiltrating lymphocytes is usually a marker of a 
good prognosis and is associated with prolonged survival 
of cancer patients.24,25 Nevertheless, the protective functions 
of the immune system, in which normal conditions are 
essential to induce immune tolerance to self-antigens, may 
also provide the means for tumor escape. Thymus-derived 
or peripherally induced Foxp3+ T
regs
 act to inhibit autoim-
mune responses, but in the tumor microenvironment, these 
cells have the ability to suppress the tumor-specific T-cell 
response via the production of immunosuppressive cytok-
ines (IL-10 and TGF-β) and via the expression of negative 
co-stimulatory molecules (CTLA-4, PD-1, and PD-L1). An 
increased number of Foxp3+ T
regs
 has been found in the blood 
of patients with cancer.26 Myeloid-derived suppressor cells 
(MDSCs) play key roles in the inhibition of host-protective 
antitumor responses via the induction of T
regs
.9 In addi-
tion, IDO, which is an enzyme involved in the tryptophan 
catabolism pathway, may elicit the suppression of T and 
natural killer cells, the generation and activation of T
regs
 and 
MDSCs, and the promotion of tumor angiogenesis. IDO is 
also overexpressed in TCs.27
The TCs can also induce an upregulation of CTLA-4 for 
their own advantage. The CTLA-4/B7 engagement inhibits 
lymphocyte activation and proliferation, which may alter the 
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Figure 1 immunoediting mechanism.
Notes: immunoediting occurs in three phases: elimination, equilibrium, and escape. elimination is a phase in which both innate and adaptive immunities are successful 
in eliminating tumor cells before clinical investigation is even possible. equilibrium is when tumor cells survive the elimination phase but keep coexisting with their host 
while being strictly controlled by immune defenses. escape is when tumor cells gain the ability to circumvent immune responses and emerge as progressively growing, 
visible tumors.
Abbreviations: DC, dendritic cell; M0, macrophage; NK, natural killer cell; Treg, regulatory T-cell; MDSC, myeloid-derived suppressor cell.
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immune response and promote tumor escape. The interaction 
of PD-1 and its ligand has also been described to negatively 
regulate the proliferation and cytokine production of T-cells. 
The ability of TCs to induce a hostile microenvironment 
through immunosuppression is a significant barrier to effec-
tive cell-mediated immunity and immunotherapy.26
Mechanism of action of emerging 
immunotherapies such as PD-1 
inhibitors
Mechanisms that are used by cancer cells to evade the host 
immune response are valuable targets for immunotherapy. 
The loss of antigen expression and resistance to cytotoxicity 
are the two ways that TCs overcome immunity. Most likely, 
cells with those advantages experience random mutations 
and natural selection because T-cells or phagocytes do not 
easily destroy them. Cancer cells, however, can also change 
their microenvironment to an immunosuppressive state via 
cytokine expression (TGF-β, VEGF, or IDO) (Figure 1). 
In addition, through the recruitment of T
regs
 (a subtype of 
helper T-cells) and MDSCs, TCs can actively induce a 
state of immunosuppression. Thus, with the ultimate goal 
of reshaping the tumor microenvironment, several immu-
notherapeutic strategies that inhibit tumor-induced immu-
nosuppression have been developed. Specifically, the use 
of mAbs directed at PD-1, PD-L1, and CTLA-4 has shown 
promising results.28
CTLA-4 was the first immune checkpoint receptor to 
be a clinical target. This protein is normally expressed 
on the plasma membranes of T
regs
 and memory T-cells. 
There, it downregulates T-cell activation by competing 
with CD28 for its ligands, CD80 and CD86, and by induc-
ing cell cycle arrest in T-cells.29 CTLA-4, whose action 
occurs 24–48 hours after antigen presentation, primarily 
regulates CD4+ T-cells and enhances the immunosuppres-
sive activity of T
regs
.30 PD-1 allows for immune resistance 
because it leads to the inhibition of effector T-cell activity 
when it binds to ligands such as PD-L1, which is a protein 
expressed by tumor and stromal T
regs
. Similar to CTLA-4, 
PD-L1 can also compete with CD28. Because cancer cells 
induce a microenvironment that is highly populated by T
regs
, 
they are very dependent on CTLA-4, PD-1, and PD-L1 
activities to promote immunosuppression.31 Ipilimumab 
and tremelimumab are mAbs that were developed to inhibit 
CTLA-4. Nivolumab, pembrolizumab, atezolizumab, and 
durvalumab were developed to inhibit PD-1 and PD-L1. 
Through a reduction in immune checkpoint activity in a 
T
reg
-rich microenvironment, they are able to diminish tumor 
evasion (Figure 2).32
Currently, preclinical studies of CTLA-4 and PD-1 
showed that the inhibition of either of these pathways stimu-
lates an antitumor immune response, which increases their 
validity as therapeutic targets. Furthermore, other studies 
based on different trials have shown that patients whose 
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Figure 2 Mechanism of action of immune checkpoint inhibitors.
Notes: Tregs depend on the activity of CTLA-4, PD-1, and PD-L1 to induce immunosuppression. ipilimumab and tremelimumab are monoclonal antibodies that inhibit 
CTLA-4, while nivolumab, pembrolizumab, atezolizumab, and durvalumab inhibit PD-1 and PD-L1. These drugs act by reducing immuno checkpoint activity on a Treg-rich 
microenvironment, thus diminishing tumor evasion.
Abbreviations: Tregs, regulatory T-cells; TCR, T-cell receptor; MHC, major histocompatibility complex.
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tumors overexpress PD-L1 tend to demonstrate an increased 
response to anti-PD-L1-directed therapy.33
Efficacy and safety of 
immunotherapy for NSCLC
A blockade of immune checkpoints, including the inhibition 
of the CTLA-4 and PD-1/PD-L1 pathways, has introduced 
a new era in cancer treatment, as advances in intratumoral 
immune responses have been observed in numerous preclini-
cal studies.34 This section features the major results of Phase 
I–III trials that primarily involve the efficacy and safety of the 
use of mAbs in NSCLC, as well as studies of a combination 
of these immunotherapies (Table 1).
Anti-PD-1 mAb inhibitors
Nivolumab
Nivolumab is a fully humanized IgG4 mAb that targets PD-1. 
This mAb has shown anticancer activity against several tumor 
types including NSCLC.35 The first Phase I clinical trial 
of an anti-PD-1 antibody showed activity in NSCLC, and 
subsequent studies have demonstrated that a PD-1 pathway 
blockade supports durable tumor responses.36 Completed 
Phase I and II clinical trials have recently led to the FDA 
approval of second-line chemotherapy treatment for resistant 
squamous NSCLC.37
In a Phase I study of ~300 patients with advanced solid 
tumors, 22 (17%) of 129 patients with NSCLC achieved an 
interesting objective response after nivolumab treatment. 
Treatment with nivolumab also resulted in an OS rate of 42% 
(95% confidence interval [CI] 33–50) at 1 year, 24% (95% 
CI 17–33) at 2 years, and 18% (95% CI 11–25) at 3 years; 
similar results have been reported for the nonsquamous and 
squamous histological subtypes.35 In another Phase I study 
that included 122 patients with NSCLC, nivolumab was 
administered once every 2 weeks at doses of 0.1–10 mg/kg. 
The results of this study showed that the objective response 
rate (ORR) across all doses was 18% (95% CI 11–29). 
Previously, patients were highly treated (54% received more 
than three lines of chemotherapy), and responses were seen 
across all dose levels; however, the ORR was longer for the 
3 mg/kg dose (32%).3
The safety of nivolumab in patients with NSCLC, specifi-
cally in those with squamous cell cancer, was established in 
a Phase II trial (CHECKMATE-063) in patients who had 
progressed after systemic chemotherapy. The most common 
AEs were fatigue (50%), dyspnea (38%), musculoskeletal 
pain (36%), decreased appetite (35%), cough (32%), nausea 
(29%), and constipation (24%). Serious AEs occurred in 59% 
of patients and included dyspnea, pneumonia, exacerbation 
of COPD, pneumonitis, pleural effusion, and hemoptysis. 
These adverse reactions led to the discontinuation of treat-
ment in 27% of patients.38
One randomized trial, in which patients received mono-
therapeutic nivolumab (3 mg/kg every 2 weeks, intravenously) 
or docetaxel (75 mg/m2 every 3 weeks, intravenously), 
showed that the median OS was higher in patients in the 
nivolumab group than in the docetaxel group (9.2 versus 
6.0 months) (95% CI 7.3–13.3) (hazard ratio [HR] 0.59, 95% 
CI 0.44–0.79; P,0.001). At 1 year, the OS rate was 42% (95% 
CI 34–50) in the nivolumab group and 24% (95% CI 17–31) 
Table 1 Efficacy and safety of immunotherapies for NSCLC
Immunotherapy Phase N Primary end point Results
Nivolumab ii35 202 Efficacy At 1 year, OS was longer with nivolumab than with docetaxel
ii38 129 Safety Serious Aes occurred in 59% of patients
Pembrolizumab ii/iii44 1,034 Efficacy OS was longer with pembrolizumab (10 mg/kg) than with pembrolizumab 
(2 mg/kg) or docetaxel (12.7 versus 10.4 versus 8.5 months)
i42 495 Safety Fatigue, pruritus, and decreased appetite are the most common Aes
Atezolizumab ii47 144 Efficacy OS was longer with atezolizumab than with docetaxel (12.6 versus 9.7 months)
i45 64 Safety No dose-limiting toxicities were reported, and there were no cases  
of grade $3 pneumonitis
ipilimumab ii36 204 Efficacy irPFS was longer in the paclitaxel and carboplatin plus ipilimumab group than 
in the paclitaxel and carboplatin plus placebo group (5.6 versus 4.6 months)
Safety irAes were more frequent in the ipilimumab group arms (19% in the 
concurrent arm versus 15% in the phased arm versus 6% in the placebo)
Tremelimumab ii32 87 Efficacy At 3 months, the PFS was longer with tremelimumab than with best supportive 
care (20% versus 14.3%, respectively)
Safety Only the tremelimumab group (20.5%) experienced grade 3/4 Aes, mainly 
diarrhea and colitis
Abbreviations: NSCLC, non-small-cell lung cancer; OS, overall survival; Aes, adverse effects; irPFS, immune-related PFS; irAes, immune-related Aes; PFS, progression-free 
survival.
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in the docetaxel group. Nine (7%) out of 131 patients in the 
nivolumab group and 71 (55%) out of 129 in the docetaxel 
group had grade 3/4 treatment-related adverse events.39
The successful use of nivolumab as a second-line therapy 
has led to studies of nivolumab as a first-line treatment. 
Currently, nivolumab is being studied in a Phase I trial to 
assess its safety and tolerability as a first-line combination 
therapy or monotherapy in chemotherapy-naïve patients.40
Pembrolizumab
Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4 
kappa isotype that blocks the interaction between PD-1 and its 
ligands, PD-L1 and PD-L2.38 The results of the KEYNOTE-
010 trial support the recent approval of pembrolizumab for 
the management of advanced NSCLC.41
Based on a Phase I clinical trial of 495 patients who 
received pembrolizumab, fatigue, pruritus, and decreased 
appetite are its most common AEs. A clear difference based 
on the dose or schedule was demonstrated.42 In terms of 
safety, another study showed that grade 3/4 AEs occurred in 
only 6% of this population. Recently, the use of pembroli-
zumab (10 mg/kg every 2 or 3 weeks) showed an ORR of 
36% in patients with advanced NSCLC.43
In terms of efficacy, a large randomized Phase II/III 
study was performed at 202 academic medical centers in 
24 countries and involved 1,034 patients with previously 
treated NSCLC. The tumors of these patients expressed 
PD-L1 on at least 1% of TCs. Patients in this trial demon-
strated that the median OS was 10.4 months with 2 mg/kg 
of pembrolizumab, 12.7 months with 10 mg/kg of pembroli-
zumab, and 8.5 months with docetaxel. The OS was longer 
for 2 mg/kg pembrolizumab versus docetaxel (HR 0.71, 95% 
CI 0.58–0.88; P=0.0008) and for 10 mg/kg pembrolizumab 
versus docetaxel (HR 0.61, 95% CI 0.49–0.75; P=0.004). 
Furthermore, among patients with at least 50% of TCs that 
expressed PD-L1, the OS was significantly longer with 
2 mg/kg of pembrolizumab than with docetaxel (14.9 versus 
8.2 months; HR 0.54, 95% CI 0.38–0.77; P=0.0002) and with 
10 mg/kg of pembrolizumab than with docetaxel (17.3 versus 
8.2 months; HR 0.50, 95% CI 0.36–0.70; P,0.0001).44
Anti-PD-L1 mAb inhibitors
Atezolizumab
Atezolizumab (MPDL3280A) is an engineered human IgG1 
mAb against PD-L1.3 A Phase I study investigated the use 
of the atezolizumab in pretreated advanced cancer patients 
at doses between 1 and 20 mg/kg given three times per 
week. Approximately, 23 patients with advanced NSCLC 
were studied for safety and 41 for efficacy and response. 
As a result, the ORR and 6-month progression-free survival 
(PFS) rate were 21% and 45%, respectively. No maximum 
tolerated dose or dose-limiting toxicities were reported, and 
there were no cases of grade $3 pneumonitis.45
According to preliminary data from a Phase I expansion 
study in 37 patients with evaluable NSCLC, four of five 
(80%) with strong PD-L1 expression found by immunohis-
tochemistry responded to atezolizumab versus only four of 
28 patients (14%) who were PD-L1-negative. These results 
were confirmed in a later analysis of the full dataset of 
53 patients with NSCLC. High PD-L1 expression on tumor-
infiltrating ICs was significantly correlated with response to 
atezolizumab (P=0.0015), while high PD-L1 expression by 
TCs was not correlated with response to this drug (P=0.920). 
The ORR in patients with the highest level of PD-L1 expres-
sion on ICs was 83%, while the ORR in patients with high 
tumor PD-L1 expression was only 38%. On the contrary, 
the response rates were 14%–20% in patients with no or low 
PD-L1 expression, respectively.46
The single-group Phase II trial BIRCH showed that 
atezolizumab monotherapy (1,200 mg, intravenously, every 
3 weeks until disease progression, unacceptable toxicity, 
or loss of clinical benefit) demonstrated efficacy in 659 
assessable patients with PD-L1-selected stage IIIB/IV or 
recurrent NSCLC without active central nervous system 
metastases.47 The population (24%–27%) that achieved 
an objective response comprised patients who showed the 
highest expression of PD-L1 on TCs or ICs.17 Another 
randomized Phase II trial, POPLAR, included patients with 
nonsquamous or squamous NSCLC with disease progression 
after platinum treatment. In this trial, 144 patients received 
atezolizumab monotherapy (1,200 mg, intravenously, 
every 3 weeks), and 143 received docetaxel (75 mg/m2, 
intravenously, every 3 weeks). The results showed that in 
the intention-to-treat population, the median OS was longer 
in the atezolizumab group compared with the docetaxel 
group (12.6 versus 9.7 months; HR 0.73, 95% CI 0.53–0.99; 
P=0.040). In addition, patients with the highest PD-L1 
expression on their TCs or ICs showed the largest improve-
ment. Unexpected AEs did not occur in either study. The 
results from both studies indicate that the selection of patients 
according to PD-L1 expression could enable the identifica-
tion of those who are likely to benefit from atezolizumab 
treatment.47 Currently, the aim of several ongoing trials is 
to evaluate atezolizumab in pretreated advanced NSCLC 
(NCT01846416) and the use of this drug in a first-line setting 
(NCT02409342, NCT02367781, and NCT02367794).3
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Durvalumab
Durvalumab (MEDI4736) is a human IgG1 anti-PD-L1 
antibody that has shown a satisfactory safety profile and 
antitumor activity.48 Currently, there is an ongoing placebo-
controlled durvalumab trial (called PACIFIC) in patients 
with stage III unresectable NSCLC following definitive 
chemoradiation; other studies are likely to be conducted in 
the future.49
Anti-CTLA-L4 mAb inhibitors
ipilimumab
Ipilimumab is a fully humanized IgG1 anti-CTLA-4 mAb 
that blocks the binding of CTLA-4 to its ligand. In terms 
of efficacy, a randomized Phase II clinical trial assessed 
treatment with paclitaxel and carboplatin with or without 
ipilimumab in treatment-naïve stage IV NSCLC patients. 
The patients showed improvement in immune-related PFS 
when ipilimumab was administered after chemotherapy 
(5.7 versus 4.6 months; P=0.05).34 According to a subset 
analysis, the immune-related PFS in the phased cohort was 
longer in patients with squamous histology (HR 0.55) than 
in patients with nonsquamous histology (HR 0.82, 95% 
CI 0.52–1.28).36
A recent report that pooled data from clinical trials of 
ipilimumab showed that ~20% of patients will have a long-
term survival of at least 3 years after ipilimumab therapy and 
that the longest reported survival reached 10 years.29
In terms of safety, grade 3/4 AEs occurred with similar 
frequency across the different arms (control, 37%; concur-
rent, 41%; phased, 39%), although grade 4 events appeared 
more frequently in the ipilimumab arms. Among a total 
of 204 patients, serious immune-related events, includ-
ing rash (4%), colitis (10%), and hypophysitis (one case), 
occurred with similar frequency as in previous studies of 
ipilimumab.50
Currently, an ongoing Phase III clinical trial is testing 
whether ipilimumab plus paclitaxel and carboplatin will 
extend the lives of patients with squamous NSCLC more than 
placebo plus paclitaxel and carboplatin (ClinicalTrials.gov 
identifier: NCT01285609).
Tremelimumab
Tremelimumab is a fully humanized IgG2 mAb to CTLA-4.22 
One randomized Phase II trial involved 87 advanced NSCLC 
patients with stable disease who responded after four cycles 
of first-line platinum-based chemotherapy. The patients were 
randomized between tremelimumab (15 mg/kg) and best sup-
portive care (BSC). As a result, the rate of PFS at 3 months 
was similar in each arm, with 20% (90% CI 11.4–33.7) and 
14.3% (90% CI 6.4–26.3) in the tremelimumab and BSC 
arms, respectively.32
In terms of safety, the incidence of grade 3/4 AEs was 
20.5% in the tremelimumab group (n=44) and 0% in the BSC 
group (n=43); the most common grade 3/4 AEs due to the use 
of tremelimumab were diarrhea and colitis (9.1%).51
Combining anti-PD-1, anti-PD-L1, 
and anti-CTLA-4 therapies
New studies of novel approaches that incorporate check-
point inhibitors have shown promising preliminary results, 
and durable responses have been obtained in patients with 
NSCLC. The combination of two immunotherapies that tar-
get a variety of signaling pathways has added an additional 
treatment modality to immuno-oncology.34
A completed study in mice demonstrated that, com-
pared with single checkpoint inhibition, double blockade 
promoted tumor repression in 67% (two-thirds) of mice.25 
Some current studies are focused on the combination of 
checkpoint inhibitors; for example, CA209-012 is an ongo-
ing Phase I trial that aims to compare nivolumab as a mono-
therapy or combined with chemotherapy, targeted therapy, 
or ipilimumab in patients with NSCLC (ClinicalTrials.gov 
identifier: NCT01454102).
The results from a Phase I study of the combination of 
nivolumab and ipilimumab were recently presented. This 
study divided the patients into two groups: the first arm 
received 1 mg/kg of nivolumab plus 3 mg/kg of ipilimumab, 
while the second arm was given 3 mg/kg of nivolumab plus 
1 mg/kg of ipilimumab for four cycles. Both arms then 
received 3 mg/kg of nivolumab until disease progression or 
unacceptable toxicity occurred.25 In terms of efficacy, the 
ORR was 11% and 13% for patients in the first arm with 
squamous and nonsquamous histology, respectively, and was 
33% and 13% for the corresponding groups of patients in the 
second arm. The ORR, in turn, was higher in the nivolumab 
(3 mg/kg) and ipilimumab (1 mg/kg) treatment arm. After a 
comparison of the PFS at 24 weeks, the results showed ORRs 
of 41% versus 29% (the first arm versus the second arm). 
Grade 3/4 AEs were reported in 49% of patients across both 
arms. An analysis showed that the most common severe AEs 
were pneumonitis, diarrhea, colitis, elevated advanced solid 
tumors, and ALT enzymes. Three of the 49 patients died due 
to drug-related toxicities.25
Another Phase I trial that assessed the combination of 
immunotherapies was performed by Rizvi et al and showed 
that durvalumab (20 mg/kg every 2 or 4 weeks) plus 
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tremelimumab (1 mg/kg every 4 weeks) has a manageable 
tolerability profile and antitumor activity in patients with 
NSCLC. Despite the benefit of anti-PD-1/PD-L1 mono-
therapy, the combination of durvalumab plus tremelimumab 
appears to be effective regardless of PD-L1 status, even in 
patients with no PD-L1 staining in the TC membrane; this 
is a setting where patients would not be expected to derive 
significant benefit from anti-PD-1/PD-L1 monotherapy over 
the current standard of care.48
Currently, other clinical trials are ongoing and involve dif-
ferent combinations of immunotherapies. Tremelimumab is 
being studied in combination with durvalumab (MEDI4376) 
for advanced NSCLC (ClinicalTrials.gov identifier: 
NCT2000947, NCT02453282, and NCT02352948). Other 
studies of ipilimumab plus pembrolizumab in KEYNOTE-
021 and of ipilimumab plus atezolizumab are being pur-
sued (ClinicalTrials.gov identifier: NCT02039674 and 
NCT02174172, respectively).
Chimeric antigen receptor T-cells
Targeted immunotherapies using chimeric antigen recep-
tors (CARs) to redirect and reprogram patient T-cells have 
shown promising results in the treatment of acute lympho-
blastic leukemia and non-Hodgkin’s lymphoma. CARs are 
genetically engineered synthetic receptors that endow T-cells 
with the ability to target specific tumor surface antigens. 
Second-generation CARs, which combine the activation and 
co-stimulatory signaling domains, have enabled the design 
of more potent T-cells that can mediate complete responses 
in patients with chemo-refractory B-cell malignancies. 
Although the therapeutic potential of CAR T-cells against 
solid cancers remains unknown, a recent study has indicated 
the therapeutic potential of regional CAR T-cell therapy for 
pleural malignancies (both primary and metastatic). Through 
CAR T-cells that are specific to mesothelin, a cell surface 
molecule that is overexpressed in .90% of epithelioid 
malignant pleural mesotheliomas, the authors show that early 
antigen activation of mesothelin by CD4+ CAR T-cells can 
lead to enhanced antitumor efficacy.20,21
Impact of patient-focused 
perspectives such as QoL
In spite of the advances in immune checkpoint inhibitors 
for NSCLC treatment, due to unrestrained T-cell activation, 
immunotherapy can lead to manifestations of toxicity, such as 
autoimmune breakthrough or immune-related adverse events 
(irAEs).52 During the past 2 decades until 2010, 32 mAbs 
have been approved by the FDA for use as drugs, but two 
of the three drugs that might be the focus of clinical trials 
have been removed from the market due to the occurrence 
of severe AEs in human patients.53
Both education and communication among patients, 
caregivers, and the clinical team are vital for appropriate 
recognition and management of irAEs.52 For instance, the 
most common AEs in patients who receive ipilimumab 
include fatigue, diarrhea, rash, pruritus, and colitis. In addi-
tion, irAEs that result from the use of PD-1 inhibitors are 
similar. In an assessment of patients with NSCLC who were 
treated with immune checkpoint inhibitors, it is extremely 
important to recognize that immunotherapy is different from 
chemotherapy; the irAEs observed with immunotherapy have 
a completely distinct underlying mechanism compared with 
the toxicity that is observed with chemotherapy.52
In this context, even though the OS is an important 
outcome with respect to which treatment a patient should 
receive, the possible AEs and the symptomatic benefits of 
therapy must always be considered. Although assessment 
of QoL is greatly important to patients and clinicians, the 
evaluation of QoL data is a feature in a minority of trials of 
patients with NSCLC, and has contributed to the failure of 
lung cancer research.54
Some tools help researchers to assess QoL. Among them, 
the Lung Cancer Symptom Scale consists of a lung cancer-
specific measure of QoL. This scale is used particularly in 
clinical trials and assesses six common symptoms associated 
with lung cancer, such as loss of appetite, fatigue, cough, 
dyspnea, hemoptysis, and pain.55 This evaluation involves the 
use of the visual analog scale. Furthermore, other methods 
include the background demographic questionnaire and the 
Palliative Performance Scale. The latter, which is adapted 
from the Karnofsky Performance Rating Scale, rates physical 
performance and has five functional dimensions: ambulation, 
activity level and evidence of disease, self-care, oral intake, 
and level of consciousness. The Karnofsky Performance 
Rating Scale ranged from 0% (death) to 100% (fully ambu-
latory and healthy).55
Positive outcomes including improved QoL, improved 
mood, care that is directed less at an increase in lifespan, and 
longer survival have been demonstrated from the delivery 
of palliative care services that are integrated into oncology 
care among patients with advanced cancers.24 Reinke et al 
found that, among patients with stage IV lung cancer, the 
weekly assessment of symptoms in the outpatient setting by 
a palliative care team improved the QoL and the symptom 
burden and increased survival, compared with patients in a 
traditional treatment setting.24
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Currently, with attention focused on immune checkpoint 
inhibitors, several questions about irAEs will likely be 
resolved with more widespread clinical trials. It is not 
clear, for instance, if autoimmune disease is an absolute 
contraindication for this type of therapy. In this context, 
studies that identify biomarkers and other factors involved 
in response and resistance to immunotherapy, in addition 
to trials that assess the combination of immunotherapy 
and chemotherapy, targeted therapy, or multiple immune 
modulators, are underway to better define this treatment 
modality for cancer.52
Conclusion
Considering all the aspects discussed in this manuscript, it is 
noteworthy that immuno checkpoint inhibitors have estab-
lished a new era for the treatment of advanced NSCLC. The 
large set of susceptible patients for this scenario emerges 
concurrently with the competitive research trials among the 
main pharmaceutical sponsors and clinical research officers 
in an attempt to find the best setting for their innovative 
drugs. Nevertheless, this is a very difficult task because the 
data change rapidly and sometimes show the limitations and 
important concerns of the current trial designs. The major 
sponsors and clinical research officers have launched several 
of the current trials in the last 3–5 years. This has led to the 
identification of potential limitations, such as the biomarker 
selection implementation (eg, in the case of PD-L1 expres-
sion as an inclusion criterion, which would restrict patient 
selection and possible benefits), as well as the image response 
criteria assessment protocols (eg, CheckMate 063 assessed 
the ORR using the traditional Response Evaluation Criteria in 
Solid Tumors version 1.1 criteria, which was not appropriate 
for immunotherapy).56 Advances in research are occurring 
more quickly than changes in traditional practices, and per-
haps, some protocol amendments are difficult to implement 
in such multicentric randomized control trials. However, 
the data regarding the outcomes, toxicity profile control, 
cost-effective analysis, and patient QoL have emerged in 
an attempt to determine the best approaches to improve 
patient care.
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